Published in Curr Infect Dis Rep on April 01, 2003
How I treat HIV-associated lymphoma. Blood (2012) 1.42
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med (1995) 6.77
Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood (1996) 4.22
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 3.03
Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet (1982) 2.58
Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol (2000) 2.55
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 2.47
Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med (1993) 2.27
Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. MMWR Morb Mortal Wkly Rep (1985) 2.26
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer (1997) 1.82
Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer (1991) 1.81
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood (1994) 1.79
Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68
Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS (2001) 1.63
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood (1998) 1.63
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol (2001) 1.55
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 1.52
Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood (2001) 1.52
Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS (1997) 1.51
Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology (1994) 1.46
Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood (1994) 1.38
Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr (2002) 1.28
Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol (1999) 1.24
Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood (2001) 1.23
Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol (1999) 1.20
P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer (1991) 1.19
Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer (1999) 1.15
Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res (1986) 1.08
Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin's lymphoma. Blood (1995) 1.08
Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood (1993) 1.05
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol (1993) 1.03
Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol (1999) 1.03
Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS (2001) 1.02
Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol (1997) 1.01
HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA (2001) 0.96
Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog (1998) 0.94
Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie (2001) 0.89
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res (2002) 0.88
Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res (2002) 0.84
bcl-2 proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphoma. Histopathology (1994) 0.83
Molecular pathogenesis of HIV-associated lymphomas. AIDS Res Hum Retroviruses (1992) 0.82
AIDS-associated malignant lymphoma. Med Clin North Am (1992) 0.82
Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer (2001) 0.81
Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males. Blood (1985) 0.80
Epidemiology, clinical characteristics, and management of AIDS-related lymphoma. Hematol Oncol Clin North Am (1991) 0.80
The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention. Leuk Lymphoma (1992) 0.80
Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med (1993) 0.79
Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma (1994) 0.79
Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations. Br J Haematol (1998) 0.79
Etiology and pathogenesis of AIDS-related non--Hodgkin's lymphoma. Hematol Oncol Clin North Am (1996) 0.79
Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy. Int J STD AIDS (1998) 0.79
Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Haematologica (1996) 0.77
Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. AIDS (2001) 0.77
Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res (2002) 0.77
Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients. Can J Neurol Sci (2002) 0.77
Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol (1994) 0.76
Chemotherapy for AIDS-related lymphomas. N Engl J Med (1997) 0.75
m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol (1990) 0.75
Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: preliminary results. Cancer Res (1992) 0.75
[Non-Hodgkin's lymphoma and AIDS: histopathologic features]. Arch Anat Cytol Pathol (1992) 0.75
Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr (1993) 0.75
Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci (1990) 0.75